Tongji Hospital Tongji Medical,Science & Technology Trials

Tongji Hospital Tongji Medical,Science & Technology	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Fishman, Sigal

ABTECT, NCT05535946: - Maintenance

Recruiting

1050

Europe, Canada, Japan, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

01/26

01/30

LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis

Recruiting

1063

Europe, Canada, Japan, US, RoW

Mirikizumab, LY3074828

Eli Lilly and Company

Ulcerative Colitis

07/26

12/27

Ivanoiu, Adrian

TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting

1500

Europe, RoW

Donanemab, (LY3002813), Placebo

Eli Lilly and Company

Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders

04/27

PD-INHIB, NCT05209516: Study of Motor Inhibition in Parkinson's Disease and Focal Hand Dystonia

Recruiting

N/A

200

Europe

Behavioral data, Single-pulse transcranial magnetic stimulation (TMS), Questionnaires, MDS (Movement Disorder Society) UPDRS (Unified Parkinson's Disease Rating Scale) Part 3 (Motor Part)

Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain

Parkinson Disease

04/23

Santos, Emerson

SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting

1016

Europe, Canada, Japan, US, RoW

LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed

Eli Lilly and Company, Loxo Oncology, Inc.

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

10/26

10/29

Tang, Yamei

AGREE, NCT05910125: Aspirin Combined With Clopidogrel Versus Intravenous Alteplase for Acute Minor Stroke

Not yet recruiting

472

RoW

Aspirin, Clopidogrel, Alteplase

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Ischemic Stroke

07/27

NCT04818099: Vortioxetine in the Treatment of Depression Associated With Head and Neck Cancers Undergoing Radiotherapy

Recruiting

208

RoW

Vortioxetine 10 mg, Placebo

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Sun Yat-sen University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Brain Hospital Affiliated to Guangzhou Medical University

Radiation Injuries

10/23

04/24

PEARL, NCT05856851: Intra-arterial Alteplase for Acute Ischemic Stroke After Mechanical Thrombectomy

Recruiting

324

RoW

Alteplase, Intra-arterial alteplase after mechanical thrombectomy

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Shenzhen Hospital of Southern Medical University

Stroke, Acute Ischemic

12/25

TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting

1500

Europe, RoW

Donanemab, (LY3002813), Placebo

Eli Lilly and Company

Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders

04/27

NCT06413654: A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)

Recruiting

2/3

132

RoW

B001, Placebo

Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd

Neuromyelitis Optica Spectrum Disorders

10/27

02/29

NCT03342443: Effect of Memantine on Radiotherapy-related Cognitive Impairment

Recruiting

2/3

240

RoW

Memantine, Arm I, Placebo, Arm II

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Cognitive Impairment

10/24

12/24

NCT05811442: Study of 50561 in Patients With Mild or Moderate Alzheimer's Disease

Recruiting

RoW

50561 high dose, 50561 low dose, Placebo

Beijing Joekai Biotechnology LLC

Alzheimer's Disease

05/24

06/24

NCT03907371: The Effect of Donepezil in Radiotherapy-related Cognitive Impairment.

Recruiting

238

RoW

Donepezil Hydrochloride, Placebo

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Radiation Injuries, Cognitive Impairment

12/22

PASS, NCT05861765: The Efficacy of Papaverine to Prevent Radial Artery Spasm During Transradial Cerebral Angiography

Recruiting

240

RoW

Papaverine Hydrochloride, normal saline

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Radial Artery Spasm

09/23

10/23

BRAIN, NCT05303259: Effect of Bevacizumab on Asymptomatic Radiotherapy-induced Brain Injury

Recruiting

204

RoW

Bevacizumab

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Brain Injuries

12/24

12/25

CRYSTAL, NCT06766916: Crisugabalin for Radiotherapy-Related Neuropathic Pain

Not yet recruiting

172

RoW

Crisugabalin, Pregabalin

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Neuropathic Pain

11/26

12/26

NCT06044350: A Clinical Trial of BAT4406F Injection in Patients with Neuromyelitis Optica Spectrum Disorders

Recruiting

162

RoW

BAT4406F Injection, BAT4406F Placebos

Bio-Thera Solutions

Optic Neuromyelitis Spectrum Disease

05/25

05/26

RELAX, NCT05543239: Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation on Radiotherapy-Related Neuropathic Pain

Recruiting

N/A

116

RoW

Transcutaneous Auricular Vagus Nerve Stimulation(TaVNS), Sham Transcutaneous Auricular Vagus Nerve Stimulation(SS)

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Neuropathic Pain, Radiotherapy Side Effect

11/23

03/24

NCT06221267: A Registry Study on Rimegepant for the Treatment of Migraine Participants in Guangdong-Hong Kong-Macao Greater Bay Area

Recruiting

N/A

120

RoW

Rimegepant

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Migraine

05/24

06/24

PROEM, NCT06225947: Patient-Reported Outcomes for Lemborexant in Chinese Participants With Insomnia

Recruiting

N/A

200

RoW

Lemborexant 5 MG, DAYVIGO

Guangdong Provincial People's Hospital, Nanfang Hospital, Southern Medical University

Insomnia

03/25

06/25

MAGIC, NCT06437600: Immediate Angioplasty For Acute Ischemic Stroke With Severe Intracranial Atherosclerotic Stenosis

Not yet recruiting

N/A

418

RoW

Immediate angioplasty

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Shenzhen Hospital of Southern Medical University

Stroke, Acute Ischemic

12/29

NCT03908502: A Study in Radiotherapy-related Nervous System Complications

Recruiting

N/A

4000

RoW

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Nervous System Complication

12/37

NCT04360200: Cognitive Impairment in Ageing People

Recruiting

N/A

5000

RoW

Yamei Tang

MCI, Alzheimer Disease, VAD - Vascular Dementia, Cognitive Impairment

12/40

Zhang, Min

HS-10234-401, NCT06743438: Long-term Safety and Efficacy of Tenofovir Amibufenamide in Patients With CHB

Active, not recruiting

640

RoW

Tenofovir Amibufenamide（TMF）, HS-10234

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Hepatitis B, Chronic

06/24

09/29

NCT04565262: Study on Antiviral Therapy for HBeAg-positive Chronic Hepatitis B Patients Aged 1-16 Years

Not yet recruiting

200

RoW

NAs+IFN-α

Beijing 302 Hospital

HBeAg Positive Chronic Hepatitis B

07/23

09/23

ERASE, NCT06093191: Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis

Recruiting

364

RoW

Tobramycin Inhalant Product, Inhaled antibiotics, Ciprofloxacin 750 MG, Oral antibiotics, Oral ciprofloxacin placebo, Natural saline inhalation, Inhaled saline

Shanghai Pulmonary Hospital, Shanghai, China

Bronchiectasis Adult, Pseudomonas Aeruginosa Infection

10/25

12/25

NCT04381143: ASPIrin in Reducing Events in Dialysis ( ASPIRED )

Recruiting

9000

RoW

Aspirin 100 mg Oral Tablet, Matching Placebo

Guangdong Provincial People's Hospital, The George Institute

CKD (Chronic Kidney Disease) Stage 5D

09/26

12/26

CRAD-001-03, NCT05295173: A Study of r-PA Treating Patients With Acute Ischemic Stroke（RAISE）

Completed

1412

RoW

Injection of recombinant human tissue plasminogen kinase derivatives, Reteplase, brand name: Ruitongli, r-PA, Recombinant human tissue plasminogen activator, Alteplase, brand name: Actilyse, rt-PA

Angde Biotech Pharmaceutical Co., Ltd., Beijing Tiantan Hospital

Acute Ischemic Stroke

06/23

NCT05745259: Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients （3T Stroke-Ⅲ）

Recruiting

1630

RoW

Alteplase, rt-PA, Tenecteplase, TNK-tPA

Beijing Tiantan Hospital, Jiangsu FENG HUA Biotech Pharmaceutical Co., Ltd, The Place Pharmaceutical(Jiangsu) Co., Ltd

Acute Ischemic Stroke

11/23

03/24

STEP, NCT06465485: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma

Recruiting

500

RoW

Benralizumab, Fasenra

AstraZeneca

Severe Eosinophilic Asthma

10/25

08/26

NCT06323213: Efficacy and Safety Study of 610 in Patients With Severe Asthma

Not yet recruiting

480

610, Placebo

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Asthma

06/26

09/26

NCT05975268: A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis

Active, not recruiting

747

RoW

JS005 (recombinant humanized monoclonal antibody against IL-17A)

Shanghai Junshi Bioscience Co., Ltd.

Moderate to Severe Chronic Plaque Psoriasis

08/25

10/25

TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting

1500

Europe, RoW

Donanemab, (LY3002813), Placebo

Eli Lilly and Company

Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders

04/27

NCT05528679: A Phase II Study of 610 in Participants With Severe Eosinophilic Asthma

Not yet recruiting

120

RoW

610 100mg, 610 300mg, placebo

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Asthma

09/23

NCT06438757: Trial of JYB1904 in Patients With Allergic Asthma

Recruiting

RoW

JYB1904, Omalizumab

Jemincare

Allergic Asthma

10/25

NCT06109818: Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis

Recruiting

129

RoW

ICP-488 Tablets, ICP-488 Placebo

Beijing InnoCare Pharma Tech Co., Ltd.

Moderate to Severe Plaque Psoriasis

10/24

11/24

NCT05593575: Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease

Recruiting

320

RoW

SPH3127+SPH3127matching placebo+valsartan matching placebo, SPH3127+valsartan matching placebo, SPH3127 matching placebo+valsartan

Shanghai Pharmaceuticals Holding Co., Ltd

Diabetic Kidney Disease

06/25

NCT06680947: A Phase IIb Study of 610 in Participants With Severe Eosinophilic Asthma

Not yet recruiting

225

610, Placebo

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Asthma

09/26

04/27

TQC2731-Ⅱ-04, NCT06707883: A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Recruiting

258

RoW

TQC2731 injection, TQC2731 Placebo

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

Chronic Obstructive Pulmonary Disease

12/26

09/27

NCT04562870 / 2020-003809-60: A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis

	Jul 2023 - Dec 2023 : Top-line data from XPORT-MF-035 trial for myeloﬁbrosis
	First patient dosed as a monotherapy in patients with 2L myelofibrosis
	Dec 2021 - Dec 2021: First patient dosed as a monotherapy in patients with 2L myelofibrosis

Active, not recruiting

112

Europe, US, RoW

Selinexor, Physician's Choice Treatment

Karyopharm Therapeutics Inc

Myelofibrosis

01/25

NCT06122831: A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)

Recruiting

1/2

RoW

TQ05105 Tablets, TQB3617 Capsules

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Myelofibrosis

12/26

04/27

NCT05584306: A Dose Ranging Placebo-controlled Double-blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of 610 in Participants With Severe Eosinophilic Asthma

Active, not recruiting

RoW

610 30mg group, 610 100mg group, 610 300mg group, Placebo 30mg group, Placebo 100mg group, Placebo 300mg group

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Asthma

09/23

NCT06199700: Esketamine for the Treatment of Rett Syndrome

Active, not recruiting

RoW

Esketamine hydrochloride

Children's Hospital of Fudan University

Rett Syndrome

10/24

05/25

CARTinNS, NCT04561557: Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System

Recruiting

RoW

CT103A cells, Cyclophosphamide and fludarabine

Tongji Hospital, Nanjing IASO Biotechnology Co., Ltd.

Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Neuromyelitis Optica Spectrum Disorder, Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Idiopathic Inflammatory Myopathies, Multiple Sclerosis, Autoimmune Encephalitis, Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), POEMS Syndrome

02/27

05/27

SAFE-APD, NCT03598387: Automated Peritoneal Dialysis Versus Intermittent Hemodialysis in Acute Kidney Injury

Recruiting

N/A

100

RoW

Automated peritoneal dialysis, Intermittent hemodialysis

Limeng Chen, First Hospital of China Medical University, First Affiliated Hospital Xi'an Jiaotong University, Beijing Anzhen Hospital, Xiangya Hospital of Central South University, Baxter Healthcare Corporation

Acute Kidney Injury

12/22

NCT06393257: Airway Clearance Technique of Oscillation and Lung Expansion in Bronchiectasis

Recruiting

N/A

RoW

Oscillation and Lung Expansion, Postural drainage, Anti-infective therapy, Mucolytic

Shanghai Pulmonary Hospital, Shanghai, China

Bronchiectasis Adult

09/25

05/26

NCT05293405: Neuroinflammatory PET Imaging in Autoimmune Encephalomyelitis

Recruiting

N/A

100

RoW

18F-DPA-714 PET

Ruijin Hospital

Autoimmune Encephalomyelitis

12/23

12/24

NCT05845151: Fibroblast Activating Protein Inhibitor PET Imaging in Lupus Nephritis

Recruiting

N/A

RoW

68Ga-FAPI-04 PET

Ruijin Hospital

Lupus Nephritis

12/23

04/24

NCT05371873: A Study of Chromosomal Abnormalities as a Predictor of Staging and Prognosis in Patients With Liver Cancer

Active, not recruiting

N/A

250

RoW

Liver resection method

First Affiliated Hospital of Zhejiang University

Hepatocellular Carcinoma

03/25

COAST, NCT03653156: China Cognition and Aging Study

Recruiting

N/A

100000

RoW

Capital Medical University, Beijing Tiantan Hospital, Beijing Chao Yang Hospital, Fu Xing Hospital, Capital Medical University, Peking Union Medical College Hospital, Peking University First Hospital, Peking University Third Hospital, Chinese PLA General Hospital, China-Japan Friendship Hospital, Beijing Geriatric Hospital, The First Affiliated Hospital of Dalian Medical University, Fujian Medical University Union Hospital, Guangzhou Psychiatric Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, First Affiliated Hospital of Guangxi Medical University, The Affiliated Hospital Of Guizhou Medical University, Handan Central Hospital, Hebei General Hospital, First Hospital of Shijiazhuang City, Tangshan Worker's Hospital, Hunan Provincial People's Hospital, Kaifeng Central Hospital, People's Hospital of Zhengzhou University, Wuhan University Zhongnan Hospital, First Affiliated Hospital of Harbin Medical University, Tongji Hospital, People's Hospital Affiliated Hubei Medical University, The Third Xiangya Hospital of Central South University, Xiangya Hospital of Central South University, The First Hospital of Jilin University, China-Japan Union Hospital, Jilin University, Subei People's Hospital of Jiangsu, Nantong University Affiliated Hospital, Mineral General Hospital, Xuzhou, Jiangxi Provincial People's Hopital, Anshan Central Hospital, The Affiliated Zhongshan Hospital of Dalian University, First Hospital of China Medical University, Baotou Central Hospital, General Hospital of Ningxia Medical University, The People's Hospital of Ningxia, The Affiliated Hospital of Qingdao University, The 960th Hospital of PLA, Qilu Hospital of Shandong University, Qilu Hospital of Shandong University (Qingdao), Shandong Provincial Hospital, Qingdao Municipal Hospital, The First Affiliated Hospital of Shanxi Medical University, Tang-Du Hospital, First Affiliated Hospital Xi'an Jiaotong University, Ruijin Hospital, RenJi Hospital, Shanghai Changzheng Hospital, Afﬁliated Hospital of North Sichuan Medical College, Tianjin Huanhu Hospital, Tianjin Medical University General Hospital, Traditional Chinese Medicine Hospital of Xinjiang Autonomous Region, Ningbo Medical Center Lihuili Hospital, First Affiliated Hospital of Wenzhou Medical University, First Affiliated Hospital of Zhejiang University, Shao Yifu Hospital of Zhejiang Medical University, Zhejiang Provincial People's Hospital, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, The Second Affiliated Hospital of Chongqing Medical University, The First Affiliated Hospital of Anhui Medical University, People's Hospital of Chongqing, Dongfang Hospital Beijing University of Chinese Medicine, Zigong No.1 Peoples Hospital

Mild Cognitive Impairment(MCI), Alzheimer Disease, Late Onset, Familial Alzheimer Disease (FAD), Vascular Dementia (VaD), Normal Control, Non-Alzheimer Degenerative Dementia

01/38

CFAN, NCT03657732: The Chinese Familial Alzheimer's Network

Recruiting

N/A

40000

RoW

Capital Medical University, Beijing Tiantan Hospital, Beijing Chao Yang Hospital, Fu Xing Hospital, Capital Medical University, Peking Union Medical College Hospital, Peking University First Hospital, Peking University Third Hospital, Chinese PLA General Hospital, China-Japan Friendship Hospital, Beijing Geriatric Hospital, The First Affiliated Hospital of Dalian Medical University, Fujian Medical University Union Hospital, Guangzhou Psychiatric Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, First Affiliated Hospital of Guangxi Medical University, The Affiliated Hospital Of Guizhou Medical University, Handan Central Hospital, Hebei General Hospital, First Hospital of Shijiazhuang City, Tangshan Worker's Hospital, Henan Provincial People's Hospital, Kaifeng Central Hospital, People's Hospital of Zhengzhou University, First Affiliated Hospital of Harbin Medical University, Tongji Hospital, People's Hospital Affiliated Hubei Medical University, Wuhan University Zhongnan Hospital, The Third Xiangya Hospital of Central South University, Xiangya Hospital of Central South University, The First Hospital of Jilin University, China-Japan Union Hospital, Jilin University, Subei People's Hospital of Jiangsu, Nantong University Affiliated Hospital, Mineral General Hospital, Xuzhou, Jiangxi Provincial People's Hopital, Anshan Central Hospital, The Affiliated Zhongshan Hospital of Dalian University, First Hospital of China Medical University, Baotou Central Hospital, General Hospital of Ningxia Medical University, The People's Hospital of Ningxia, The Affiliated Hospital of Qingdao University, The 960th Hospital of PLA, Qilu Hospital of Shandong University, Qilu Hospital of Shandong University (Qingdao), Shandong Provincial Hospital, Qingdao Municipal Hospital, The First Affiliated Hospital of Shanxi Medical University, Tang-Du Hospital, First Affiliated Hospital Xi'an Jiaotong University, Ruijin Hospital, RenJi Hospital, Shanghai Changzheng Hospital, Afﬁliated Hospital of North Sichuan Medical College, Tianjin Huanhu Hospital, Tianjin Medical University General Hospital, Traditional Chinese Medicine Hospital of Xinjiang Autonomous Region, Ningbo Medical Center Lihuili Hospital, First Affiliated Hospital of Wenzhou Medical University, First Affiliated Hospital of Zhejiang University, Shao Yifu Hospital of Zhejiang Medical University, Zhejiang Provincial People's Hospital, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, The Second Affiliated Hospital of Chongqing Medical University, The First Affiliated Hospital of Anhui Medical University, People's Hospital of Chongqing, Dongfang Hospital Beijing University of Chinese Medicine, Zigong No.1 Peoples Hospital

Alzheimer Disease, Familial Alzheimer Disease (FAD)

01/38

NCT04694430: A Multi-center Study to Determine the Prevalence and Influence of Pertussis on COPD Exacerbation in Shenzhen

Not yet recruiting

N/A

500

RoW

Blood sample, Data collection, Throat swab

Shenzhen People's Hospital

COPD Exacerbation, Pertussis

06/21

12/21

Dong, Lingli

NCT06499233: Efficacy and Safety of Prophylactic Treatment for Pneumocystis Jirovecii Pneumonia in Patients With Autoimmune Inflammatory Rheumatic Disease

Recruiting

800

RoW

Trimethoprim/Sulfamethoxazole, TMP/SMX

Tongji Hospital

Pneumonia, Pneumocystis, Autoimmune Inflammatory Rheumatic Disease, Autoimmune Diseases, Connective Tissue Disease, Prevention

07/26

12/26

RESOLUTION-1, NCT05516758: A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis

Completed

491

Europe, Canada, Japan, US, RoW

Peresolimab, Placebo

Eli Lilly and Company

Rheumatoid Arthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases, Connective Tissue Diseases, Autoimmune Diseases, Immune System Diseases

11/23

01/25

NCT05588908: A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout

Recruiting

1/2

120

RoW

Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg (phase Ib), SSGJ-613 100 mg (phase Ib), Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase Ib), SSGJ-613 200 mg (phase Ib), Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 300 mg (phase Ib), SSGJ-613 300 mg (phase Ib), Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase II), SSGJ-613 200 mg (phase II), Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection low dose 300 mg (phase II), SSGJ-613 300 mg (phase II), Compound Betamethasone Injection (phase II), Placebo (phase II), PBO

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Acute Gout

09/23

11/23

NCT06497361: Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease

Recruiting

RoW

PRG-2311

Tongji Hospital, Shenzhen Pregene Biopharma Co., Ltd.

Lupus Nephritis, IgG4-related Disease

07/27

07/28

NCT06497387: Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease

Recruiting

RoW

PRG-1801

Tongji Hospital, Shenzhen Pregene Biopharma Co., Ltd.

Lupus Nephritis, IgG4-related Disease

07/27

07/28

NCT06458803: Efficacy and Safety of Eltrombopag for Refractory Thrombocytopenia Associated With Connective Tissue Disease

Completed

N/A

Eltrombopag, Promacta

Tongji Hospital

Refractory Thrombocytopenia, Connective Tissue Diseases

05/23

11/23

NCT06277427: Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells

Recruiting

N/A

RoW

PRG-1801 （CAR-T against BCMA）

Lingli Dong, Shenzhen Pregene Biopharma Co., Ltd.

Lupus Nephritis, ANCA Associated Vasculitis

02/26

01/27

Eremina, Natalia

NCT04250311: Clinical Trial of Efficacy and Safety of ММН-407 in the Treatment of Influenza in Outpatient Adults

Suspended

314

RoW

MMH-407, Raphamin, Placebo

Materia Medica Holding

Influenza

12/24

NCT05364671: Clinical Trial of Efficacy and Safety of Raphamin in the Treatment of Coronavirus Disease 2019 in Outpatients

Completed

771

RoW

Raphamin, MMH-407, Placebo

Materia Medica Holding

Coronavirus Disease 2019 (COVID-19)

08/23

LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis

Recruiting

1063

Europe, Canada, Japan, US, RoW

Mirikizumab, LY3074828

Eli Lilly and Company

Ulcerative Colitis

07/26

12/27

Jia, Jianjun

TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting

1500

Europe, RoW

Donanemab, (LY3002813), Placebo

Eli Lilly and Company

Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders

04/27

NCT06151795: A Study to Evaluate XTR006 in Chinese Volunteers

Completed

RoW

XTR006

Sinotau Pharmaceutical Group

Alzheimer Disease

09/23

01/24

NCT06151808: Analysis of XTR006 PET Imaging in Non-cognitively Impaired Subjects, MCI Due toAD, and Mild to Moderate AD Subjects

Completed

N/A

RoW

XTR006

Sinotau Pharmaceutical Group

Alzheimer Disease

11/23

01/24

COAST, NCT03653156: China Cognition and Aging Study

Recruiting

N/A

100000

RoW

Mild Cognitive Impairment(MCI), Alzheimer Disease, Late Onset, Familial Alzheimer Disease (FAD), Vascular Dementia (VaD), Normal Control, Non-Alzheimer Degenerative Dementia

01/38

CFAN, NCT03657732: The Chinese Familial Alzheimer's Network

Recruiting

N/A

40000

RoW

Capital Medical University, Beijing Tiantan Hospital, Beijing Chao Yang Hospital, Fu Xing Hospital, Capital Medical University, Peking Union Medical College Hospital, Peking University First Hospital, Peking University Third Hospital, Chinese PLA General Hospital, China-Japan Friendship Hospital, Beijing Geriatric Hospital, The First Affiliated Hospital of Dalian Medical University, Fujian Medical University Union Hospital, Guangzhou Psychiatric Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, First Affiliated Hospital of Guangxi Medical University, The Affiliated Hospital Of Guizhou Medical University, Handan Central Hospital, Hebei General Hospital, First Hospital of Shijiazhuang City, Tangshan Worker's Hospital, Henan Provincial People's Hospital, Kaifeng Central Hospital, People's Hospital of Zhengzhou University, First Affiliated Hospital of Harbin Medical University, Tongji Hospital, People's Hospital Affiliated Hubei Medical University, Wuhan University Zhongnan Hospital, The Third Xiangya Hospital of Central South University, Xiangya Hospital of Central South University, The First Hospital of Jilin University, China-Japan Union Hospital, Jilin University, Subei People's Hospital of Jiangsu, Nantong University Affiliated Hospital, Mineral General Hospital, Xuzhou, Jiangxi Provincial People's Hopital, Anshan Central Hospital, The Affiliated Zhongshan Hospital of Dalian University, First Hospital of China Medical University, Baotou Central Hospital, General Hospital of Ningxia Medical University, The People's Hospital of Ningxia, The Affiliated Hospital of Qingdao University, The 960th Hospital of PLA, Qilu Hospital of Shandong University, Qilu Hospital of Shandong University (Qingdao), Shandong Provincial Hospital, Qingdao Municipal Hospital, The First Affiliated Hospital of Shanxi Medical University, Tang-Du Hospital, First Affiliated Hospital Xi'an Jiaotong University, Ruijin Hospital, RenJi Hospital, Shanghai Changzheng Hospital, Afﬁliated Hospital of North Sichuan Medical College, Tianjin Huanhu Hospital, Tianjin Medical University General Hospital, Traditional Chinese Medicine Hospital of Xinjiang Autonomous Region, Ningbo Medical Center Lihuili Hospital, First Affiliated Hospital of Wenzhou Medical University, First Affiliated Hospital of Zhejiang University, Shao Yifu Hospital of Zhejiang Medical University, Zhejiang Provincial People's Hospital, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, The Second Affiliated Hospital of Chongqing Medical University, The First Affiliated Hospital of Anhui Medical University, People's Hospital of Chongqing, Dongfang Hospital Beijing University of Chinese Medicine, Zigong No.1 Peoples Hospital

Alzheimer Disease, Familial Alzheimer Disease (FAD)

01/38

Ye, Qinyong

TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting

1500

Europe, RoW

Donanemab, (LY3002813), Placebo

Eli Lilly and Company

Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders

04/27

NCT05906719: Machine Vision Based MDS-UPDRS III Machine Rating

Recruiting

N/A

871

RoW

video recording

Ruijin Hospital, Second Affiliated Hospital of Soochow University, Beijing Hospital, Beijing Tiantan Hospital, Wuhan Union Hospital, China, Fujian Medical University Union Hospital, Guangdong Provincial People's Hospital, West China Hospital

Parkinsonian Disorders, Machine Learning

04/24

COAST, NCT03653156: China Cognition and Aging Study

Recruiting

N/A

100000

RoW

Mild Cognitive Impairment(MCI), Alzheimer Disease, Late Onset, Familial Alzheimer Disease (FAD), Vascular Dementia (VaD), Normal Control, Non-Alzheimer Degenerative Dementia

01/38

CFAN, NCT03657732: The Chinese Familial Alzheimer's Network

Recruiting

N/A

40000

RoW

Capital Medical University, Beijing Tiantan Hospital, Beijing Chao Yang Hospital, Fu Xing Hospital, Capital Medical University, Peking Union Medical College Hospital, Peking University First Hospital, Peking University Third Hospital, Chinese PLA General Hospital, China-Japan Friendship Hospital, Beijing Geriatric Hospital, The First Affiliated Hospital of Dalian Medical University, Fujian Medical University Union Hospital, Guangzhou Psychiatric Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, First Affiliated Hospital of Guangxi Medical University, The Affiliated Hospital Of Guizhou Medical University, Handan Central Hospital, Hebei General Hospital, First Hospital of Shijiazhuang City, Tangshan Worker's Hospital, Henan Provincial People's Hospital, Kaifeng Central Hospital, People's Hospital of Zhengzhou University, First Affiliated Hospital of Harbin Medical University, Tongji Hospital, People's Hospital Affiliated Hubei Medical University, Wuhan University Zhongnan Hospital, The Third Xiangya Hospital of Central South University, Xiangya Hospital of Central South University, The First Hospital of Jilin University, China-Japan Union Hospital, Jilin University, Subei People's Hospital of Jiangsu, Nantong University Affiliated Hospital, Mineral General Hospital, Xuzhou, Jiangxi Provincial People's Hopital, Anshan Central Hospital, The Affiliated Zhongshan Hospital of Dalian University, First Hospital of China Medical University, Baotou Central Hospital, General Hospital of Ningxia Medical University, The People's Hospital of Ningxia, The Affiliated Hospital of Qingdao University, The 960th Hospital of PLA, Qilu Hospital of Shandong University, Qilu Hospital of Shandong University (Qingdao), Shandong Provincial Hospital, Qingdao Municipal Hospital, The First Affiliated Hospital of Shanxi Medical University, Tang-Du Hospital, First Affiliated Hospital Xi'an Jiaotong University, Ruijin Hospital, RenJi Hospital, Shanghai Changzheng Hospital, Afﬁliated Hospital of North Sichuan Medical College, Tianjin Huanhu Hospital, Tianjin Medical University General Hospital, Traditional Chinese Medicine Hospital of Xinjiang Autonomous Region, Ningbo Medical Center Lihuili Hospital, First Affiliated Hospital of Wenzhou Medical University, First Affiliated Hospital of Zhejiang University, Shao Yifu Hospital of Zhejiang Medical University, Zhejiang Provincial People's Hospital, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, The Second Affiliated Hospital of Chongqing Medical University, The First Affiliated Hospital of Anhui Medical University, People's Hospital of Chongqing, Dongfang Hospital Beijing University of Chinese Medicine, Zigong No.1 Peoples Hospital

Alzheimer Disease, Familial Alzheimer Disease (FAD)

01/38

Takagi, Sho

VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting

778

Europe, Canada, Japan, US, RoW

Mirikizumab, LY3074828

Eli Lilly and Company

Crohn's Disease

11/24

12/26

LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis

Recruiting

1063

Europe, Canada, Japan, US, RoW

Mirikizumab, LY3074828

Eli Lilly and Company

Ulcerative Colitis

07/26

12/27

Lee, Choon Kin

LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis

Recruiting

1063

Europe, Canada, Japan, US, RoW

Mirikizumab, LY3074828

Eli Lilly and Company

Ulcerative Colitis

07/26

12/27

Chu, Qian

FGCL-4592-898, NCT05301517: A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies

Completed

159

RoW

SEPO®, Recombinant human erythropoietin-α [rHuEPO-α], Roxadustat, FG-4592

FibroGen

Chemotherapy Induced Anemia

04/23

NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

Recruiting

522

RoW

D-1553 Tablet, Docetaxel injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Non Small Cell Lung Cancer

10/26

12/27

NCT06498479: ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer

Recruiting

460

RoW

HS-20093, Topotecan

Hansoh BioMedical R&D Company

Small Cell Lung Cancer

09/26

05/27

NCT05767892: YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Not yet recruiting

350

RoW

YK-209A tablet, Pemetrexed+carboplatin/Cisplatin

Suzhou Puhe Pharmaceutical Technology Co., LTD

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

07/25

12/26

TQB2450-AL2846-III-01, NCT05922345: Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.

Recruiting

518

RoW

TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules, TQB2450 placebo, docetaxel injection, AL2846 matching placebo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Non-small Cell Lung Cancer

08/25

12/25

SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting

1016

Europe, Canada, Japan, US, RoW

LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed

Eli Lilly and Company, Loxo Oncology, Inc.

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

10/26

10/29

NCT04106180: SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC

Recruiting

RoW

GM-CSF, Sintilimab, SBRT, Stereotactic body radiation therapy

Fudan University

NSCLC Stage IV

08/22

08/23

CAPSTONE, NCT04888429: Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma

Jan 2022 - Jun 2022 : Interim data from CAPSTONE trial for NSCLC

Recruiting

RoW

Camrelizumab, SHR-1210, Famitinib, SHR-1020

Qian Chu, Jiangsu HengRui Medicine Co., Ltd.

Sarcomatoid Carcinoma of Lung

12/24

06/25

ARISE, NCT04354961: Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell Carcinoma

Recruiting

RoW

Almonertinib, Investigational Product

Fujian Cancer Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd.

Pulmonary Adenosquamous Carcinoma

12/23

06/25

ACHELOUS, NCT06001151: Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative

Recruiting

RoW

Cadonilimab, AK104, Pemetrexed, Carboplatin

Qian Chu, Akeso Pharmaceuticals, Inc.

Carcinoma, Non-Small-Cell Lung

08/25

08/27

NCT06020066: SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI

Recruiting

202

RoW

EGFR-TK Inhibitor, Stereotactic radiotherapy

Fudan University

Brain Metastases, Non-small Cell Lung Cancer

08/28

08/29

NCT05329298: A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors

Recruiting

1/2

RoW

BPI-361175

Betta Pharmaceuticals Co., Ltd.

Non-small Cell Lung Cancer

06/23

12/23

TQB2618-TQB2450-Ib-01, NCT05645315: Clinical Trial of TQB2618 Injection Combined With TQB2450 Injection in Patients With Advanced Solid Tumors

Recruiting

1/2

127

RoW

TQB2618 injection and TQB2450 injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Advanced Solid Tumor

12/23

06/24

NCT05789602: A Study of BPI-460372 in Advanced Solid Tumor Patients

Recruiting

RoW

BPI-460372

Betta Pharmaceuticals Co., Ltd.

Advanced Solid Tumor

04/25

04/26

NCT05513664: Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer

Not yet recruiting

N/A

RoW

Osimertinib

Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations

06/23

08/23

NCT04766515: Observational Prospective Study of Immune Checkpoint Inhibitors for Solid Neoplasms

Recruiting

N/A

1500

RoW

Fudan University

Cancer

08/23

08/25

xiong, huihua

RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Recruiting

366

RoW

RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda

RemeGen Co., Ltd.

Breast Cancer

06/24

12/24

TORCHLIGHT, NCT04085276: Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment

Active, not recruiting

531

RoW

JS001, Nab-Paclitaxel, Placebo

Shanghai Junshi Bioscience Co., Ltd.

Triple-Negative Breast Cancer

12/24

12/25

EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting

866

Europe, Japan, US, RoW

Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219

Eli Lilly and Company, Eli Lilly and Company

Breast Neoplasms, Neoplasm Metastasis

06/24

08/27

TQB2102-III-01, NCT06561607: A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer

Not yet recruiting

542

RoW

TQB2102 for Injection, Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Breast Cancer

01/27

12/28

RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Active, not recruiting

2/3

301

RoW

RC48-ADC, RC48, Lapatinib, Capecitabine

RemeGen Co., Ltd.

Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases

07/24

12/24

NCT05145907: Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors

Active, not recruiting

133

RoW

TJ107 +Pembrolizumab

TJ Biopharma Co., Ltd.

Triple-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma

06/24

12/24

NCT06149130: Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer

Recruiting

RoW

Adebrelimab, SHR-1316, dalpiciclib, SHR-6390

Tongji Hospital

Breast Cancer

11/25

11/26

UTILIZABLE, NCT06125080: The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer () ：Single-arm, Prospective, Open Clinical Study

Recruiting

RoW

Utidelone, UTD1, Tirelizumab, Bevacizumab

Huihua Xiong

TNBC - Triple-Negative Breast Cancer

10/25

10/26

NCT05746728: Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer

Not yet recruiting

1/2

RoW

Surufatinib, Tislelizumab

Huihua Xiong

Metastatic Triple-negative Breast Cancer

08/24

08/25

Kim, YoungHo

ABTECT, NCT05535946: - Maintenance

Recruiting

1050

Europe, Canada, Japan, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

01/26

01/30



	Diseases Companies Products Productz Mechanisms of Action Sites